Skip to content
Stock screener

PFSA Profusa, Inc. stock chart & analysis

Conviction 49HealthcareScan · Tue, Nov 10, 2026
Bullish marubozu

Profusa, Inc. (PFSA) closed at $0.5630 (+2.40%) on Nov 10, 2026. Its latest daily candle is a bullish marubozu. Price is below its 50-day and below its 200-day moving average. RSI(14) 36, RS Rating 1, -99.8% from its 52-week high, -99.6% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.

PFSA$0.5630+2.40%
ResistanceSupportVol 14Insider buyInsider sell
Loading chart…

Why PFSA moved

From the StockSetups movers recaps that covered PFSA, newest first. A recap states what was known that day.

Profusa, Inc.Surgical & Medical Instruments & Apparatuswww.profusa.com ↗
Price0.5630
Change+2.40%
Gap+0.89%
Rel volume0.01×
Avg volume2.67M
Avg $ vol2.68M
SMA 200.7837
SMA 501.56
SMA 20015.01
Price vs 50-63.92%
Price vs 200-96.25%
MA stackbearish
50/200 cross—
Supertrenddown · 0.9707
RSI (14)36
MACD hist0.04
MACD cross—
Stoch %K / %D6 / 5
ADX (14)13
+DI / −DI28 / 26
RSI divergenceBullish
MACD divergenceBullish
ATR %38.84%
ADR %14.00%
52w high265.63
52w low0.5100
From 52w high-99.79%
Above 52w low+10.39%
New 52w highNo
SqueezeOn · 14d
Bollinger width97.42%
%B0.21
Donchian pos5.64%
Donchian high1.45
Donchian low0.5100
AVWAP (52w high)9.07
vs AVWAP high-93.80%
AVWAP (52w low)0.5352
vs AVWAP low+5.19%
OBV trendUp
Chaikin MF (20)-0.35
Today vs 20d0.01×
Avg vol (14d)3.48M
Avg vol (20d)2.67M
Avg $ vol (20d)2.68M
Market cap340.98K
RS Rating1 / 99
RS 3m (vs SPY)-38.74%
RS 6m (vs SPY)-96.53%
RS line new highNo
Trend template0/8
Technical rank3.1
1 week-8.96%
1 month-56.69%
3 months-41.66%
6 months-94.95%
1 year-99.75%
YTD-99.57%
P/E-0.01
P/B-0.01
P/S—
P/FCF-0.02
EPS-107.01
Div yield—
ROE132.06%
ROA—
Debt/Eq-0.03
Current0.03
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth-288.11%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value534.99K
Revenue—
Net income-8.76M
Gross profit—
Free cash flow-16.26M
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNasdaq
Shares out4.66M
Employees—
ListedMon, Jul 14, 2025
Free float604.36K
Float %11.3%
Short interest—
Days to cover—
Short volume42.0%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction49 / 100
Pattern quality—
Tech rank3.1 / 100
Group rank—
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmBullish marubozu

Financials as of Tue, Jun 30, 2026 · quarterly.

PFSA technical analysis

Trend

PFSA is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 63.9% below the 50-day ($1.56) and 96.3% below the 200-day ($15.01). ADX(14) at 13 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 36, in the bearish half of its range. The MACD histogram is positive. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 1 puts its weighted 12-month performance ahead of about 1% of the US market.

Volume and volatility

Volume on the latest session ran 0.0× its 20-day average. It trades about $2.7M a day on average. ATR(14) is $0.2187, 38.8% of price — its typical daily range. Bollinger Bands are in a squeeze (14 sessions) — volatility is compressed. On-balance volume is trending up. Chaikin Money Flow (-0.35) shows distribution.

Key levels

The 52-week range is $0.5100 to $265.63; price is 99.8% below the high and 10.4% above the low. The VWAP anchored at the 52-week high is $9.07, above price.

Performance

PFSA returned -9.0% (1 week), -56.7% (1 month), -41.7% (3 months), -95.0% (6 months), -99.8% (1 year), -99.6% (year to date).

About Profusa, Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Surgical & Medical Instruments & Apparatus · Listed 2025

Insider activity

SEC Form 4 transactions in PFSA · open-market 2 buys · 4 sells

InsiderSideShares
HRT FINANCIAL LP
10% owner · Common Stock · 2026-08-17
Sell18.39K
Knechtel Fred S.
Chief Financial Officer · Common Stock · 2026-08-12
Convert301.99K
Knechtel Fred S.
Chief Financial Officer · Convertible Promissory Note · 2026-08-12
Convert—
STOVER JACK E
Chief Executive Officer · Common Stock · 2026-08-12
Convert301.99K
STOVER JACK E
Chief Executive Officer · Convertible Promissory Note · 2026-08-12
Convert—
HRT FINANCIAL LP
10% owner · Common Stock · 2026-08-14
Sell3.16K
HRT FINANCIAL LP
10% owner · Common Stock · 2026-08-13
Sell42.41K
HRT FINANCIAL LP
10% owner · Common Stock · 2026-08-12
Buy5.58K
HRT FINANCIAL LP
10% owner · Common Stock · 2026-08-11
Sell2.28K
HRT FINANCIAL LP
10% owner · Common Stock · 2026-08-10
Buy4.02K

SEC filings

EDGAR filings in PFSA · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.